COMy 2017 | How can standard risk multiple myeloma (MM) patients be cured?
Philippe Moreau, MD, from the University Hospital of Nantes, Nantes, France, speaks about new possibilities to cure multiple myeloma (MM) at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. He highlights that in patients with standard risk, all the drugs that are available need to be used, in combination with stem cell transplantation and monoclonal antibodies. Prof. Moreau explains that rather than treating patients until remission, the aim is to achieve fast and deep response as well as minimal residual disease (MRD) negativity. He outlines the treatment strategy including duration of treatment and subsequent monitoring, and gives an estimate of the proportion of patients that can be cured using this approach.
